Key facts
- It has raised $160.0M; the latest was Early Stage VC ($60.0M) in Jul 2025.
- Notable investors include Shunwei Capital, Legend Star, Highlight Capital, Northern Light Venture Capital, Vertex Ventures China — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for VelaVigo
- ·The full record, as it builds
Funding rounds
No funding rounds for VelaVigo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VelaVigo
Developer of new drugs based on disease biology. The company aims to establish an innovative and systematic R&D pipeline, and establish a "closed-loop" between drug discovery and clinical practice through strong translational medicine capabilities, enabling patients with affordable and differentiated high-quality new biological drugs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Employees
- 58
- Website
- velavigo.com/
- Ownership
- Privately Held (backing)
VelaVigo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VelaVigo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VelaVigo in its N-PORT filings yet. We sweep new filings monthly.